compound glp-1 fda New project announcement: HHS‑OIG is taking a closer look at FDA's oversight of compounded GLP‑1 drugs. Although shortages ended in 2025, some facilities may still be producing these drugs at scale. Our FDA Updates on Compounded GLP-1

Blanco A, Blanco G

So far I feel great and I am less hungry

Postoperative atrial fibrillation following cardiac surgery: a persistent complication

However, it remains important to consider that GLP-1 receptor agonists may be limited by unfavorable side effects, especially in the context of PD

Extensive persistent inflammation even when SARS-CoV-2-infected cells are only sporadically present at late stages of COVID-19 (Schurink et al., 2020) could also justify low GSH levels in association with over-abundance of cellular ROS, cellular oxidative damage, increased inflammation and cell death pathways activation seen in inflammaging (Zuo et al., 2019

All descriptions are based on published research, regulatory filings, and publicly available company disclosures